Next Article in Journal
Sustaining Vaccine Confidence in the 21st Century
Next Article in Special Issue
The Potential Impact of Preventive HIV Vaccines in China: Results and Benefits of a Multi-Province Modeling Collaboration
Previous Article in Journal
Hepatitis B Vaccination in Pregnancy in the United States
Previous Article in Special Issue
Factors Affecting the Acceptance of Pandemic Influenza A H1N1 Vaccine amongst Essential Service Providers: A Cross Sectional Study
Vaccines 2013, 1(2), 174-203; doi:10.3390/vaccines1020174
Review

Tumor-Associated Glycans and Immune Surveillance

1, 2 and 1,*
1 Winthrop P. Rockefeller Cancer Institute and Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA 2 Stephan Angeloff Institute of Microbiology, BAS, Sofia 1113, Bulgaria
* Author to whom correspondence should be addressed.
Received: 18 April 2013 / Revised: 18 April 2013 / Accepted: 6 June 2013 / Published: 17 June 2013
(This article belongs to the Special Issue Feature Papers)
View Full-Text   |   Download PDF [680 KB, uploaded 17 June 2013]   |   Browse Figure

Abstract

Changes in cell surface glycosylation are a hallmark of the transition from normal to inflamed and neoplastic tissue. Tumor-associated carbohydrate antigens (TACAs) challenge our understanding of immune tolerance, while functioning as immune targets that bridge innate immune surveillance and adaptive antitumor immunity in clinical applications. T-cells, being a part of the adaptive immune response, are the most popular component of the immune system considered for targeting tumor cells. However, for TACAs, T-cells take a back seat to antibodies and natural killer cells as first-line innate defense mechanisms. Here, we briefly highlight the rationale associated with the relative importance of the immune surveillance machinery that might be applicable for developing therapeutics.
Keywords: monoclonal antibodies; immunotherapy; cancer; mimics; vaccine; TACA; glycans; tumor; carbohydrate monoclonal antibodies; immunotherapy; cancer; mimics; vaccine; TACA; glycans; tumor; carbohydrate
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Monzavi-Karbassi, B.; Pashov, A.; Kieber-Emmons, T. Tumor-Associated Glycans and Immune Surveillance. Vaccines 2013, 1, 174-203.

View more citation formats

Article Metrics

For more information on the journal, click here

Comments

Cited By

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert